Johnson & Johnson (NYSE:JNJ) Increase in stock position by NTV Asset Management LLC

0

NTV Asset Management LLC raised its position in Johnson & Johnson (NYSE: JNJ – Get Rating) by 0.7% in Q1, according to the company in its latest SEC filing. The institutional investor held 35,565 shares of the company after acquiring 237 additional shares during the quarter. Johnson & Johnson accounts for about 1.1% of NTV Asset Management LLC’s holdings, making the stock its 23rd largest holding. NTV Asset Management LLC’s holdings in Johnson & Johnson were worth $6,303,000 at the end of the most recent reporting period.

Several other hedge funds also changed their positions in the company. Patron Partners LLC increased its position in Johnson & Johnson by 12.7% in Q1. Patron Partners LLC now owns 6,625 shares of the company worth $1,174,000 after purchasing an additional 747 shares in the last quarter. Tandem Investment Advisors Inc. increased its position in Johnson & Johnson by 4.8% in the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company worth $57,867,000 after purchasing an additional 15,003 shares in the last quarter. Argent Advisors Inc. increased its position in Johnson & Johnson by 6.6% in the 1st quarter. Argent Advisors Inc. now owns 19,772 shares of the company worth $3,504,000 after buying 1,218 additional shares in the last quarter. Exeter Financial LLC increased its position in Johnson & Johnson by 3.2% in the first quarter. Exeter Financial LLC now owns 26,431 shares of the company worth $4,684,000 after buying 819 more shares last quarter. Finally, Fusion Capital LLC strengthened its position in Johnson & Johnson by 7.8% in the 1st quarter. Fusion Capital LLC now owns 27,844 shares of the company worth $4,935,000 after purchasing 2,019 additional shares in the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s shares.

Analysts set new price targets

A number of equity research analysts have published JNJ stock reports. StockNews.com upgraded Johnson & Johnson shares from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research report. Wells Fargo & Company raised its price target on Johnson & Johnson stock from $190.00 to $195.00 and gave the stock an “overweight” rating in a Wednesday, July 13 research note. Citigroup lowered its price target on Johnson & Johnson shares from $205.00 to $201.00 in a Wednesday, July 20 research note. UBS Group lowered its price target on Johnson & Johnson shares from $185.00 to $180.00 in a Thursday, July 21 research note. Finally, Daiwa Capital Markets began covering Johnson & Johnson shares in a Wednesday June 22 research note. They set an “outperformance” rating on the stock. Four analysts gave the stock a hold rating, five gave the stock a buy rating and one gave the stock a strong buy rating. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Insiders place their bets

Separately, CAO Robert J. Decker sold 8,462 shares of the company in a trade dated Thursday, May 26. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this hyperlink. Separately, CAO Robert J. Decker sold 8,462 shares of the company in a trade dated Thursday, May 26. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following completion of the transaction, the chief accounting officer now directly owns 15,473 shares of the company, valued at approximately $2,785,140. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available via this hyperlink. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a transaction dated Friday, June 10. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company, valued at $12,336,803. The disclosure of this sale can be found here. Insiders of the company own 0.35% of the shares of the company.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $165.30 on Friday. The company has a debt ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The company has a market capitalization of $434.60 billion, a price/earnings ratio of 24.06, a P/E/G ratio of 3.24 and a beta of 0.59. The company’s fifty-day moving average is $174.47 and its two-hundred-day moving average is $174.68. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.

Johnson & Johnson Inc (NYSE:JNJ – Get Rating) last released its quarterly results on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating the consensus estimate of $2.57 by $0.02. The company posted revenue of $24.02 billion for the quarter, versus analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company’s quarterly revenue increased 3.0% year over year. During the same period last year, the company posted EPS of $2.48. Equity research analysts expect Johnson & Johnson to post EPS of 10.05 for the current year.

Johnson & Johnson announces dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. The ex-date of this dividend is Monday, August 22. This represents an annualized dividend of $4.52 and a yield of 2.73%. Johnson & Johnson’s dividend payout ratio is 65.79%.

Johnson & Johnson profile

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

Read more

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.

Share.

Comments are closed.